Report cover image

Global PECAM-1 Antibody Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 215 Pages
SKU # APRC20360340

Description

Summary

According to APO Research, the global PECAM-1 Antibody market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for PECAM-1 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for PECAM-1 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the PECAM-1 Antibody market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for PECAM-1 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the PECAM-1 Antibody market include Thermo Fisher, YO Proteins, US Biological, SICGEN, Santa Cruz Biotechnology, Rockland Immunochemicals, R&D Systems, Proteintech Group and OriGene, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for PECAM-1 Antibody, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of PECAM-1 Antibody, also provides the sales of main regions and countries. Of the upcoming market potential for PECAM-1 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PECAM-1 Antibody sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PECAM-1 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PECAM-1 Antibody sales, projected growth trends, production technology, application and end-user industry.

PECAM-1 Antibody Segment by Company

Thermo Fisher
YO Proteins
US Biological
SICGEN
Santa Cruz Biotechnology
Rockland Immunochemicals
R&D Systems
Proteintech Group
OriGene
Novus Biologicals
Miltenyi Biotec
MilliporeSigma
LifeSpan Biosciences
Enzo Life Sciences
Dianova
Creative Biomart
Boster
Bon Opus Biosciences
Bio-Rad
BioLegend
Abnova
Abeomics
Abcam
PECAM-1 Antibody Segment by Type

Mouse
Rabbit
Others
PECAM-1 Antibody Segment by Application

Laboratory
Hospital
Others
PECAM-1 Antibody Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global PECAM-1 Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions PECAM-1 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify PECAM-1 Antibody significant trends, drivers, influence factors in global and regions.
6. To analyze PECAM-1 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PECAM-1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PECAM-1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PECAM-1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PECAM-1 Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PECAM-1 Antibody industry.
Chapter 3: Detailed analysis of PECAM-1 Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of PECAM-1 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of PECAM-1 Antibody in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

215 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global PECAM-1 Antibody Sales Value (2020-2031)
1.2.2 Global PECAM-1 Antibody Sales Volume (2020-2031)
1.2.3 Global PECAM-1 Antibody Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 PECAM-1 Antibody Market Dynamics
2.1 PECAM-1 Antibody Industry Trends
2.2 PECAM-1 Antibody Industry Drivers
2.3 PECAM-1 Antibody Industry Opportunities and Challenges
2.4 PECAM-1 Antibody Industry Restraints
3 PECAM-1 Antibody Market by Company
3.1 Global PECAM-1 Antibody Company Revenue Ranking in 2024
3.2 Global PECAM-1 Antibody Revenue by Company (2020-2025)
3.3 Global PECAM-1 Antibody Sales Volume by Company (2020-2025)
3.4 Global PECAM-1 Antibody Average Price by Company (2020-2025)
3.5 Global PECAM-1 Antibody Company Ranking (2023-2025)
3.6 Global PECAM-1 Antibody Company Manufacturing Base and Headquarters
3.7 Global PECAM-1 Antibody Company Product Type and Application
3.8 Global PECAM-1 Antibody Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global PECAM-1 Antibody Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 PECAM-1 Antibody Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 PECAM-1 Antibody Market by Type
4.1 PECAM-1 Antibody Type Introduction
4.1.1 Mouse
4.1.2 Rabbit
4.1.3 Others
4.2 Global PECAM-1 Antibody Sales Volume by Type
4.2.1 Global PECAM-1 Antibody Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global PECAM-1 Antibody Sales Volume by Type (2020-2031)
4.2.3 Global PECAM-1 Antibody Sales Volume Share by Type (2020-2031)
4.3 Global PECAM-1 Antibody Sales Value by Type
4.3.1 Global PECAM-1 Antibody Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global PECAM-1 Antibody Sales Value by Type (2020-2031)
4.3.3 Global PECAM-1 Antibody Sales Value Share by Type (2020-2031)
5 PECAM-1 Antibody Market by Application
5.1 PECAM-1 Antibody Application Introduction
5.1.1 Laboratory
5.1.2 Hospital
5.1.3 Others
5.2 Global PECAM-1 Antibody Sales Volume by Application
5.2.1 Global PECAM-1 Antibody Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global PECAM-1 Antibody Sales Volume by Application (2020-2031)
5.2.3 Global PECAM-1 Antibody Sales Volume Share by Application (2020-2031)
5.3 Global PECAM-1 Antibody Sales Value by Application
5.3.1 Global PECAM-1 Antibody Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global PECAM-1 Antibody Sales Value by Application (2020-2031)
5.3.3 Global PECAM-1 Antibody Sales Value Share by Application (2020-2031)
6 PECAM-1 Antibody Regional Sales and Value Analysis
6.1 Global PECAM-1 Antibody Sales by Region: 2020 VS 2024 VS 2031
6.2 Global PECAM-1 Antibody Sales by Region (2020-2031)
6.2.1 Global PECAM-1 Antibody Sales by Region: 2020-2025
6.2.2 Global PECAM-1 Antibody Sales by Region (2026-2031)
6.3 Global PECAM-1 Antibody Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global PECAM-1 Antibody Sales Value by Region (2020-2031)
6.4.1 Global PECAM-1 Antibody Sales Value by Region: 2020-2025
6.4.2 Global PECAM-1 Antibody Sales Value by Region (2026-2031)
6.5 Global PECAM-1 Antibody Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America PECAM-1 Antibody Sales Value (2020-2031)
6.6.2 North America PECAM-1 Antibody Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe PECAM-1 Antibody Sales Value (2020-2031)
6.7.2 Europe PECAM-1 Antibody Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific PECAM-1 Antibody Sales Value (2020-2031)
6.8.2 Asia-Pacific PECAM-1 Antibody Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America PECAM-1 Antibody Sales Value (2020-2031)
6.9.2 South America PECAM-1 Antibody Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa PECAM-1 Antibody Sales Value (2020-2031)
6.10.2 Middle East & Africa PECAM-1 Antibody Sales Value Share by Country, 2024 VS 2031
7 PECAM-1 Antibody Country-level Sales and Value Analysis
7.1 Global PECAM-1 Antibody Sales by Country: 2020 VS 2024 VS 2031
7.2 Global PECAM-1 Antibody Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global PECAM-1 Antibody Sales by Country (2020-2031)
7.3.1 Global PECAM-1 Antibody Sales by Country (2020-2025)
7.3.2 Global PECAM-1 Antibody Sales by Country (2026-2031)
7.4 Global PECAM-1 Antibody Sales Value by Country (2020-2031)
7.4.1 Global PECAM-1 Antibody Sales Value by Country (2020-2025)
7.4.2 Global PECAM-1 Antibody Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.5.2 USA PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.5.3 USA PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.6.2 Canada PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.6.2 Mexico PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.8.2 Germany PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.9.2 France PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.9.3 France PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.10.2 U.K. PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.11.2 Italy PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.12.2 Spain PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.13.2 Russia PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.16.2 China PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.16.3 China PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.17.2 Japan PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.18.2 South Korea PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.19.2 India PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.19.3 India PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.20.2 Australia PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.22.2 Brazil PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.23.2 Argentina PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.24.2 Chile PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.25.2 Colombia PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.26.2 Peru PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.28.2 Israel PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.29.2 UAE PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.30.2 Turkey PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.31.2 Iran PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt PECAM-1 Antibody Sales Value Growth Rate (2020-2031)
7.32.2 Egypt PECAM-1 Antibody Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt PECAM-1 Antibody Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Thermo Fisher
8.1.1 Thermo Fisher Comapny Information
8.1.2 Thermo Fisher Business Overview
8.1.3 Thermo Fisher PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.1.4 Thermo Fisher PECAM-1 Antibody Product Portfolio
8.1.5 Thermo Fisher Recent Developments
8.2 YO Proteins
8.2.1 YO Proteins Comapny Information
8.2.2 YO Proteins Business Overview
8.2.3 YO Proteins PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.2.4 YO Proteins PECAM-1 Antibody Product Portfolio
8.2.5 YO Proteins Recent Developments
8.3 US Biological
8.3.1 US Biological Comapny Information
8.3.2 US Biological Business Overview
8.3.3 US Biological PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.3.4 US Biological PECAM-1 Antibody Product Portfolio
8.3.5 US Biological Recent Developments
8.4 SICGEN
8.4.1 SICGEN Comapny Information
8.4.2 SICGEN Business Overview
8.4.3 SICGEN PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.4.4 SICGEN PECAM-1 Antibody Product Portfolio
8.4.5 SICGEN Recent Developments
8.5 Santa Cruz Biotechnology
8.5.1 Santa Cruz Biotechnology Comapny Information
8.5.2 Santa Cruz Biotechnology Business Overview
8.5.3 Santa Cruz Biotechnology PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.5.4 Santa Cruz Biotechnology PECAM-1 Antibody Product Portfolio
8.5.5 Santa Cruz Biotechnology Recent Developments
8.6 Rockland Immunochemicals
8.6.1 Rockland Immunochemicals Comapny Information
8.6.2 Rockland Immunochemicals Business Overview
8.6.3 Rockland Immunochemicals PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.6.4 Rockland Immunochemicals PECAM-1 Antibody Product Portfolio
8.6.5 Rockland Immunochemicals Recent Developments
8.7 R&D Systems
8.7.1 R&D Systems Comapny Information
8.7.2 R&D Systems Business Overview
8.7.3 R&D Systems PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.7.4 R&D Systems PECAM-1 Antibody Product Portfolio
8.7.5 R&D Systems Recent Developments
8.8 Proteintech Group
8.8.1 Proteintech Group Comapny Information
8.8.2 Proteintech Group Business Overview
8.8.3 Proteintech Group PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.8.4 Proteintech Group PECAM-1 Antibody Product Portfolio
8.8.5 Proteintech Group Recent Developments
8.9 OriGene
8.9.1 OriGene Comapny Information
8.9.2 OriGene Business Overview
8.9.3 OriGene PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.9.4 OriGene PECAM-1 Antibody Product Portfolio
8.9.5 OriGene Recent Developments
8.10 Novus Biologicals
8.10.1 Novus Biologicals Comapny Information
8.10.2 Novus Biologicals Business Overview
8.10.3 Novus Biologicals PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.10.4 Novus Biologicals PECAM-1 Antibody Product Portfolio
8.10.5 Novus Biologicals Recent Developments
8.11 Miltenyi Biotec
8.11.1 Miltenyi Biotec Comapny Information
8.11.2 Miltenyi Biotec Business Overview
8.11.3 Miltenyi Biotec PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.11.4 Miltenyi Biotec PECAM-1 Antibody Product Portfolio
8.11.5 Miltenyi Biotec Recent Developments
8.12 MilliporeSigma
8.12.1 MilliporeSigma Comapny Information
8.12.2 MilliporeSigma Business Overview
8.12.3 MilliporeSigma PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.12.4 MilliporeSigma PECAM-1 Antibody Product Portfolio
8.12.5 MilliporeSigma Recent Developments
8.13 LifeSpan Biosciences
8.13.1 LifeSpan Biosciences Comapny Information
8.13.2 LifeSpan Biosciences Business Overview
8.13.3 LifeSpan Biosciences PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.13.4 LifeSpan Biosciences PECAM-1 Antibody Product Portfolio
8.13.5 LifeSpan Biosciences Recent Developments
8.14 Enzo Life Sciences
8.14.1 Enzo Life Sciences Comapny Information
8.14.2 Enzo Life Sciences Business Overview
8.14.3 Enzo Life Sciences PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.14.4 Enzo Life Sciences PECAM-1 Antibody Product Portfolio
8.14.5 Enzo Life Sciences Recent Developments
8.15 Dianova
8.15.1 Dianova Comapny Information
8.15.2 Dianova Business Overview
8.15.3 Dianova PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.15.4 Dianova PECAM-1 Antibody Product Portfolio
8.15.5 Dianova Recent Developments
8.16 Creative Biomart
8.16.1 Creative Biomart Comapny Information
8.16.2 Creative Biomart Business Overview
8.16.3 Creative Biomart PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.16.4 Creative Biomart PECAM-1 Antibody Product Portfolio
8.16.5 Creative Biomart Recent Developments
8.17 Boster
8.17.1 Boster Comapny Information
8.17.2 Boster Business Overview
8.17.3 Boster PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.17.4 Boster PECAM-1 Antibody Product Portfolio
8.17.5 Boster Recent Developments
8.18 Bon Opus Biosciences
8.18.1 Bon Opus Biosciences Comapny Information
8.18.2 Bon Opus Biosciences Business Overview
8.18.3 Bon Opus Biosciences PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.18.4 Bon Opus Biosciences PECAM-1 Antibody Product Portfolio
8.18.5 Bon Opus Biosciences Recent Developments
8.19 Bio-Rad
8.19.1 Bio-Rad Comapny Information
8.19.2 Bio-Rad Business Overview
8.19.3 Bio-Rad PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.19.4 Bio-Rad PECAM-1 Antibody Product Portfolio
8.19.5 Bio-Rad Recent Developments
8.20 BioLegend
8.20.1 BioLegend Comapny Information
8.20.2 BioLegend Business Overview
8.20.3 BioLegend PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.20.4 BioLegend PECAM-1 Antibody Product Portfolio
8.20.5 BioLegend Recent Developments
8.21 Abnova
8.21.1 Abnova Comapny Information
8.21.2 Abnova Business Overview
8.21.3 Abnova PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.21.4 Abnova PECAM-1 Antibody Product Portfolio
8.21.5 Abnova Recent Developments
8.22 Abeomics
8.22.1 Abeomics Comapny Information
8.22.2 Abeomics Business Overview
8.22.3 Abeomics PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.22.4 Abeomics PECAM-1 Antibody Product Portfolio
8.22.5 Abeomics Recent Developments
8.23 Abcam
8.23.1 Abcam Comapny Information
8.23.2 Abcam Business Overview
8.23.3 Abcam PECAM-1 Antibody Sales, Value and Gross Margin (2020-2025)
8.23.4 Abcam PECAM-1 Antibody Product Portfolio
8.23.5 Abcam Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 PECAM-1 Antibody Value Chain Analysis
9.1.1 PECAM-1 Antibody Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 PECAM-1 Antibody Sales Mode & Process
9.2 PECAM-1 Antibody Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 PECAM-1 Antibody Distributors
9.2.3 PECAM-1 Antibody Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.